osimertinib,Nivolumab,RP-1
bicara,astrazeneca,immunogen,replimune,bms
['tagrisso', 'melanoma', 'immunogen ', '$repl', 'bicara', '$azn', '$imgn', 'replimune']
biocentury's latest asco quick takes: az s tagrisso impresses with os data. plus: replimune gains on oncolytic virus data in melanoma, and updates from immunogen and bicara $azn $repl $imgn 
The leading voice for decision-makers throughout the global biopharma ecosystem. 
Free weekly podcast "BioCentury This Week": https://t.co/6CfHh0mIT6